摘要
目的探讨人血清早期前列腺癌抗原-2(early prostate cancer antigen-2,EPCA-2)的表达与前列腺癌临床分期及内分泌治疗的关系。方法 2011年10月—2014年9月采用酶联免疫法检测EPCA-2在经病理检查证实的116例前列腺癌患者中的表达情况,临床分期Ⅱ期61例、Ⅲ期32例、Ⅳ期23例,检测342例良性前列腺增生患者血清中EPCA-2的表达情况。检测78例前列腺癌患者内分泌治疗3个月的血清EPCA-2的表达情况,临床分期Ⅱ期24例、Ⅲ期31例、Ⅳ期23例。计量资料采用t检验,P<0.05为差异有统计学意义。结果 EPCA-2的血清含量:良性前列腺增生症组为(16.42±9.34)ng/ml;前列腺癌组为(41.60±18.59)ng/ml,其中临床Ⅱ期为(39.49±17.73)ng/ml、Ⅲ期为(41.40±19.27)ng/ml、Ⅳ期为(47.47±19.45)ng/ml;经内分泌治疗后前列腺癌患者的EPCA-2水平为(5.09±4.00)ng/ml,其中临床Ⅱ期为(4.45±2.63)ng/ml、Ⅲ期为(5.25±4.82)ng/ml、Ⅳ期为(5.54±4.04)ng/ml,前列腺癌组与良性前列腺增生症组间比较差异均有统计学意义(均P<0.05)。前列腺癌临床分期各组中比较差异均无统计学意义(均P>0.05)。经内分泌治疗后的前列腺癌患者与治疗前相比差异均有统计学意义(均P<0.05),治疗后各组比较差异均无统计学意义(均P>0.05)。结论血清EPCA-2可能为新的诊断前列腺癌的血清学标志物,与前列腺癌的临床分期无关,内分泌治疗能够降低其表达水平。
Objective To investigate the expression of human serum early prostate cancer antigen-2 （EPCA-2） in adenocarcinoma of the prostate and the relationship with clinical stages and hormonal therapy.Methods The serum samples were obtained from 116 adenocarcinoma of the prostate patients,61 patients was phase Ⅱ ,32 patients was phase Ⅲ ,23 patients was phase IV ,342 benign prostatic hyperplasia patients,and the samples were obtained from 78 adenocarcinoma of the prostate patients with 3 month of hormonal therapy,24 patients was phase Ⅱ ,31 patients was phase Ⅲ ,23 patients was phase Ⅳ from October 2011 to September 2014.Using enzyme-linked immunosorbent assay to detect the levels of the EPCA-2 protein and the data was analyzed with statistics methods.Measurment data was processed by t test,the result of P〈0.05 was considered statistically significant.Results The levels of the EPCA-2 protein of different groups：the group of prostatic adenocarcinoma contain EPCA-2 as （41.60 ± 18.59） ng/ml,the group of phase Ⅱ as （39.49± 17.73） ng/ml,the group of phase Ⅲ as （41.40± 19.27） ng/ml,the group of phase IV as （47.47± 19.45） ng/ml,the benign prostatic hyperplasia patients contain EPCA-2 as （16.42±9.34） ng/ml.The levels of the EPCA- 2 protein of 78 prostate adenocarcinoma patients after hormonal therapy for 3month as （5.09 ± 4.00） ng/ml,the group of phase II as （4.45±2.63） ng/ml,the group of phase 11 as （5.25±4.82） ng/ml,the group of phase IV as （5.54±4.04） ng/ml.Using statistics analysis suggest：there were satistically significant differences among prostatic adenocarcinoma group vs the benign prostatic hyperplasia group（all P〈O.05）.There were no satistically significant differences among the prostatic adenocareinoma groups（all P〈0.05）.There were satistically significant differences between the prostatic adenoearcinoma group after hormonal therapy and before（all P〈0.05）.There were no satistically significant differences among the prostatic adenoc
出处
《社区医学杂志》
2017年第1期5-8,共4页
Journal Of Community Medicine
基金
河南省科技厅科技发展计划项目资助(122102310013)
